|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||6.47 - 6.47|
|52 Week Range||6.47 - 6.47|
|Beta (5Y Monthly)||0.10|
|PE Ratio (TTM)||22.94|
|Earnings Date||Apr 30, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Saudi Arabia will soon begin Phase III clinical trials on around 5,000 people for a COVID-19 vaccine developed by China's CanSino Biologics Inc, a Saudi health ministry spokesman said on Sunday. Last month, CanSino's co-founder said the company was in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of the vaccine candidate, Ad5-nCOV. The vaccine uses a harmless cold virus known as adenovirus type-5 (Ad5) to carry genetic material from the coronavirus into the body.
Chinese drug company Sinopharm and Parana state have agreed to launch the fourth major COVID-19 vaccine trial in Brazil and will seek regulatory approval in the next two weeks, the Brazilian partners said on Wednesday. A trial by Sinopharm would join Phase III trials already announced in Brazil by AstraZeneca, Sinovac Biotech and a Pfizer partnership with BioNTech. Jorge Callado, head of the Parana Technology Institute (Tecpar), said they would soon finalize their proposal and submit it for approval with federal health regulator Anvisa.
A coronavirus vaccine candidate developed by China National Pharmaceutical Group (Sinopharm) could be ready for public use by the end of this year, state media reported on Wednesday, ahead of a previous expectation it may become available in 2021. Sinopharm Chairman Liu Jingzhen told state broadcaster CCTV the company expects to finish late-stage human testing within about three months. Sinopharm's unit China National Biotec Group (CNBG), which is responsible for two coronavirus vaccine projects, said in June the shot may not be ready until at least 2021 as a lack of new infections in China made it difficult to find people to test it on.